May 2, 2022 10:49 AM EDT

RA-backed PepGen sets terms for upcoming IPO; Sanofi commences dosing of Denali candidate in ALS

Paul Schloesser

Associate Editor

Though the market has experienced a strong downturn this year, a precarious few companies are testing the IPO waters. And PepGen is the newest biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

RA-backed PepGen sets terms for upcoming IPO; Sanofi commences dosing of Denali candidate in ALS

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

RA-backed Pep­Gen sets terms for up­com­ing IPO; Sanofi com­mences dos­ing of De­nali can­di­date in ALS

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

RA-backed PepGen sets terms for upcoming IPO; Sanofi commences dosing of Denali candidate in ALS

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?